Health News Releases

  • Today May 17
October 25, 2019 08:00
Global Health Progress Launched to Drive Cross-sectoral Collaborations in Support of the Sustainable Development Goals (SDGs)
To support the SDGs, with a particular focus on SDG 17: Partnership for The Goals, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has launched Global Health Progre
October 23, 2019 19:10
Covetrus Announces CEO and Chairman Transition
Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, today announced that Benjamin Shaw has stepped down as the company’s president and chief executive officer and will t
October 23, 2019 17:01
Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) today announced that Takeda has acquired an exclusive global license to
October 23, 2019 11:06
Solasia Announces Approval of episil® oral liquid in South Korea
Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today officially announced that e
October 22, 2019 11:13
ResMed Introduces AirFit N30, World’s First Tube-Down Nasal Cradle CPAP Mask
ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit N30, the world’s first tube-down nasal cradle CPAP mask with a front-facing tube - a brand-new option for sleep apnea treatment. ResMed’s light
October 21, 2019 16:43
Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFα Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from a retrospective chart review study (EVOLVE), which investigated the likelihood of serious adverse even
October 21, 2019 13:18
New Research Reveals Updated Patient Preferences on Digital Health Technology
ResMed (NYSE: RMD, ASX: RMD) today announced results from a company-led survey, revealing new patient preferences on digital health technology. The survey highlights a reason for optimism that the mar
October 21, 2019 10:35
Concept Medical is Granted CE Certification for Their Sirolimus Coated MagicTouch Group of Products
The CE certified products/brands are as listed below: 1. MagicTouch - PTA (Sirolimus Coated PTA Balloon Catheter) for peripheral arterial disease 2. MagicTouch - ED (Sirolimus Coated Balloon Cathe
October 18, 2019 13:10
Sonion Joins Global Qualcomm Extension Program
Sonion®, global leader in designing and manufacturing components and solutions for hearing aids, in-ear earphones and hearables/wearables, today announced that it is now a member of the Qualcomm® Exte
October 17, 2019 14:20
Johns Hopkins Center for Health Security, World Economic Forum and Bill & Melinda Gates Foundation Host Pandemic Exercise and Livestream
The Johns Hopkins Center for Health Security, with the World Economic Forum and the Bill & Melinda Gates Foundation, will host Event 201, a multimedia global pandemic exercise on Friday, Oct. 18, 2019
October 17, 2019 11:25
Accomplishments of Dr. Steven Rosenberg in Cancer Immunotherapy Inspire Young Researchers in Japan & XIV Fujio Cup Quiz on Stem Cells Is Won by India.
Utilizing the capability of one’s own immune system to tackle cancer, an out-of-the box idea was the brain child of Dr. Steven Rosenberg almost three decades ago. His initiative which paved way for a
October 17, 2019 10:45
Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CF™ 1)
Boehringer Ingelheim today announced the first patient enrolled in its Phase II clinical trial BALANCE-CF™ 1 to evaluate a new potential treatment for cystic fibrosis.[1,2] The trial will investigate
October 16, 2019 13:33
Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced it
October 15, 2019 16:23
Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharm
October 15, 2019 09:29
Analysis of Patients With Prior Gastrectomy Treated With LONSURF® (trifluridine/tipiracil) Published in JAMA Oncology
Servier and its partner Taiho Oncology, Inc. (US), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today that detailed results from the analysis of patients with prior gastrectomy en
October 11, 2019 11:41
Perspectum announces partnership with Precious Medical Centre
Perspectum, the leading provider of diagnostic solutions for metabolic disease and cancer, is partnering Precious Medical, a premier imaging centre in Singapore, following a successful launch event th
October 10, 2019 17:26
Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
Galderma, a global leader focused on meeting the world's increasing skin health needs, announced that it has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigat
October 10, 2019 16:44
National Institute for Health and Clinical Excellence Maintains Previous Recommendation for EXOGEN® Ultrasound Bone Healing System
Bioventus, a global leader in orthobiologic solutions, has received notice from the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) that it has updated its guidance (MTG1
ABB's mobile and autonomous YuMi® laboratory robot concept will be designed to work alongside medic
October 10, 2019 11:02
ABB Demonstrates Concept of Mobile Laboratory Robot for Hospital of the Future
ABB today opened its first global healthcare research hub on the Texas Medical Center (TMC) campus, in Houston, Texas - showcasing a number of concept technologies, including a mobile YuMi® robot, whi
October 10, 2019 10:48
Samsung Bioepis Presents Real-world Data of BENEPALI™ (etanercept) in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
Samsung Bioepis Co., Ltd. today announced real-world data of BENEPALI™ in patients with moderate to severe psoriasis from the British Association of Dermatologists Biologics and Immunomodulators Regis
October 04, 2019 19:25
MPEG LA Announces Peer Reviewed Article Featured in Nucleic Acid Therapeutics
World technology licensing leader MPEG LA today announced publication of a peer reviewed article in the October 2019 issue of Nucleic Acid Therapeutics on MPEG LA’s proprietary Increscent Therapeutics
October 01, 2019 16:37
New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes
Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olod
October 01, 2019 16:29
Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio
Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refrac
October 01, 2019 12:05
Update of Summary of Product Characteristics for Nuwiq® includes data on effective bleed protection with twice-weekly dosing with personalised prophylaxis
Octapharma announced today that the European Medicines Agency has authorised an updated Summary of Product Characteristics (SmPC) for Nuwiq® that includes information on personalised prophylaxis in pa
September 30, 2019 15:43
INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases[1]
Boehringer Ingelheim announced today that in the Phase III INBUILD® trial nintedanib slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline
25 per page50 per page75 per page100 per page